Annual revenue fell from KRW 13.6 billion in 2022 to KRW 11.6 billion in 2023, a 14.6% decline, recovered to KRW 12.4 billion in 2024 with a 6.4% increase, and then dropped to KRW 11 billion in 2025, down 11.4%. Among 2022 to 2025, 2022 was the largest year by revenue and 2025 the smallest.
The operating loss ran at KRW 1.27 billion in 2022, KRW 3.54 billion in 2023, KRW 3.12 billion in 2024 and KRW 1.7 billion in 2025, a continuous loss streak across the four years from 2022 to 2025. The operating margin moved from -9.3% in 2022 to -15.5% in 2025.
In its 2025 annual disclosure, the company cited a higher share of new products, a lower R&D spend (down from 19% to 14% of revenue) and cost-improvement activities as the main drivers.
Gross profit rose from KRW 1.06 billion in 2024 to KRW 2.88 billion in 2025, suggesting cost improvement was central to the narrower operating loss. The net loss attributable to controlling shareholders narrowed from KRW 3.36 billion in 2024 to KRW 1.13 billion in 2025.
Operating cash flow went from KRW -82.93 million in 2022 to KRW -2.15 billion in 2025, a larger outflow. On a quarterly basis, the operating loss was KRW 585 million in Q3 2025, KRW 299 million in Q4 2025 and KRW 0.57 million in Q1 2026, then widened again to KRW 407 million in Q2 2026 and KRW 404 million in Q3 2026.
Net income attributable to controlling shareholders turned positive at KRW 237 million in Q1 2026, then posted losses of KRW 264 million in Q2 and KRW 713 million in Q3. Q3 2026 revenue of KRW 3.14 billion rose 18.7% year on year, yet the higher sales did not translate into a smaller net loss.
The debt ratio of 15.0% at end-2025 is low, so the key question is profit recovery rather than balance sheet strain.